Age-Related Pharmacokinetic Changes in the Elderly
Aging alters how drugs move through the body across all four pharmacokinetic domains: absorption, distribution, metabolism, and excretion. The net effect is that many drugs accumulate and clear more slowly in older patients, raising the risk of toxicity and adverse effects. Framing prescribing decisions around these changes—along with proactive deprescribing and estimating GFR rather than trusting the raw creatinine—is central to safe geriatric care.
Absorption
Absorption undergoes minimal change with aging and is generally the least clinically important pharmacokinetic parameter in the elderly. Unlike distribution, metabolism, and excretion, it does not meaningfully drive drug accumulation or dosing adjustments in most older patients.
Distribution
Aging increases body fat while decreasing total body water and serum albumin. As a result, lipophilic drugs accumulate in the expanded fat compartment, prolonging their effect, and the reduced albumin increases the free (active) fraction of highly protein-bound drugs. Both changes heighten the potential for exaggerated or prolonged drug effects.
Metabolism
Overall hepatic drug clearance falls with age, driven mainly by reduced hepatic blood flow and decreased liver mass. Phase I oxidative reactions (cytochrome P450) tend to be more affected and variable, whereas Phase II conjugation reactions (e.g., glucuronidation) are relatively preserved. The practical result is that many liver-metabolized drugs persist longer and can accumulate, increasing the risk of toxicity if doses are not adjusted.
Excretion
Glomerular filtration rate (GFR) falls with aging even when the serum creatinine is normal, because reduced muscle mass keeps creatinine deceptively low. Renally cleared drugs therefore accumulate. This is why an estimated GFR (eGFR) should be calculated—using creatinine-based formulas such as Cockcroft-Gault or CKD-EPI—rather than relying on serum creatinine alone, which underestimates renal impairment in the elderly.
Safe Prescribing Framework
Because these pharmacokinetic shifts converge to increase drug accumulation and adverse effects, safe geriatric prescribing means knowing the Beers Criteria high-risk medication categories, estimating GFR to guide renal dosing, recognizing and avoiding the prescribing cascade, and deprescribing proactively. Medication review is essential in any older patient presenting with falls, confusion, or functional decline.
Clinical Correlate: Polypharmacy and Falls
The consequences of these changes are seen vividly in multifactorial falls. High-risk agents such as anticholinergics (diphenhydramine, oxybutynin), benzodiazepines (alprazolam), long-acting sulfonylureas (glyburide, chlorpropamide), and NSAIDs (ibuprofen) commonly accumulate or cause sedation, confusion, hypoglycemia, orthostasis, and renal injury—driving falls and functional decline. The Beers Criteria specifically flag long-acting sulfonylureas such as glyburide (glibenclamide) and chlorpropamide for prolonged hypoglycemia; shorter-acting agents like glipizide are preferred in older adults. Deprescribing these high-risk medications is a core management step.
High-yield
- Absorption changes minimally with aging and is the least clinically important parameter.
- Aging body composition: ↑ fat, ↓ water, ↓ albumin.
- Lipophilic drugs accumulate in the expanded fat compartment of older adults.
- Decreased albumin raises the free (active) drug fraction of protein-bound drugs.
- ↓ Hepatic blood flow and ↓ liver mass reduce hepatic clearance; Phase I (CYP) reactions are more affected while Phase II conjugation is relatively preserved.
- GFR declines with aging even when serum creatinine is normal.
- Calculate an estimated GFR (eGFR) using Cockcroft-Gault or CKD-EPI—creatinine alone underestimates renal impairment in the elderly.
- Know Beers Criteria high-risk categories, avoid the prescribing cascade, and deprescribe proactively.
- Long-acting sulfonylureas (glyburide, chlorpropamide) cause prolonged hypoglycemia—glipizide is preferred in the elderly.
- Anticholinergics and benzodiazepines contribute to confusion and falls in older patients.
Pitfalls
- Assuming a normal serum creatinine means normal renal function—GFR is often reduced in the elderly.
- Overlooking that renally cleared drugs accumulate even with 'normal' labs.
- Dosing lipophilic drugs as in younger patients, ignoring accumulation from increased body fat.
- Forgetting that reduced albumin increases free drug levels despite a normal total drug concentration.
- Focusing on absorption when it is the least clinically relevant change.
- Assuming all hepatic metabolism uniformly declines—Phase II conjugation is relatively preserved, while Phase I oxidation and hepatic blood flow are the main contributors to reduced clearance.
- Mislabeling glipizide as a high-risk long-acting sulfonylurea—it is actually shorter-acting and preferred; glyburide and chlorpropamide are the agents to avoid.
- Failing to review medications in an elderly patient with falls, confusion, or functional decline.
Clinical pearls
- When an older patient falls or becomes confused, review the medication list first.
- A 'normal' creatinine in a frail elder can hide significant renal impairment—calculate an estimated GFR.
- Lipophilic drugs act longer in the elderly because of an expanded fat reservoir.
- Slower hepatic and renal clearance means 'start low, go slow' and deprescribe proactively.
- Choose glipizide over glyburide in older adults to minimize prolonged hypoglycemia.
Frequently asked
Why does absorption matter least among the pharmacokinetic changes of aging?
Absorption changes minimally with aging, so it rarely drives drug accumulation or dosing decisions—unlike distribution, metabolism, and excretion, which change more substantially.
How does body composition change with aging affect drug distribution?
Aging increases body fat and decreases total body water and albumin. Lipophilic drugs accumulate in fat, and lower albumin increases the free, active fraction of protein-bound drugs.
Why should you estimate GFR in elderly patients instead of trusting the creatinine?
GFR falls with aging even when serum creatinine is normal, because reduced muscle mass keeps creatinine low. Creatinine therefore underestimates renal impairment, so calculate an estimated GFR (eGFR) with a creatinine-based formula (Cockcroft-Gault or CKD-EPI) to guide renal dosing of accumulating drugs.
What happens to hepatic drug metabolism with age?
Overall hepatic clearance falls, mainly from reduced hepatic blood flow and liver mass. Phase I (CYP-mediated) reactions are more variably affected, while Phase II conjugation is relatively preserved, so many liver-metabolized drugs persist longer and can accumulate.
Why are the elderly more prone to drug toxicity overall?
Reduced hepatic and renal clearance, accumulation of lipophilic drugs in fat, and increased free drug fraction from low albumin all combine to prolong drug effects and raise toxicity risk.
Which sulfonylurea should be avoided in the elderly, and which is preferred?
Avoid long-acting sulfonylureas—glyburide (glibenclamide) and chlorpropamide—which the Beers Criteria flag for prolonged hypoglycemia. Glipizide is shorter-acting and preferred in older adults because of its lower hypoglycemia risk.
Which prescribing strategies reduce medication harm in older adults?
Know the Beers Criteria high-risk categories, calculate an estimated GFR to guide renal dosing, recognize and avoid the prescribing cascade, and deprescribe proactively.
How do these pharmacokinetic changes relate to falls in the elderly?
Accumulating high-risk drugs like anticholinergics, benzodiazepines, long-acting sulfonylureas, and NSAIDs cause sedation, confusion, hypoglycemia, orthostasis, and renal injury—contributing to multifactorial falls, so medication review and deprescribing are essential.
Turn this into reasoning you can use on exam day — practice Age-Related Pharmacokinetic Changes on branching cases where your decisions shape the patient.